Stage I and II Small-Cell Lung Cancer—New Challenge for Surgery

Fabian Doerr1 · Sebastian Stange2 · Maximilian Michel3 · Georg Schlachtenberger1 · Hruy Menghesha1 · Thorsten Wahlers1 · Khosro Hekmat1 · Matthias B. Heldwein1

Received: 4 January 2022 / Accepted: 3 June 2022 / Published online: 30 June 2022 © The Author(s) 2022

Abstract
Purpose The recommended treatment for small-cell lung cancer (SCLC) currently is surgery in stage I disease. We wondered about stage II SCLC and present a meta-analysis on mean-survival of patients that underwent surgery for stage I and II compared to controls.

Methods A systematic literature search was performed on December 01st 2021 in Medline, Embase and Cochrane Library. We considered studies published on the effect of surgery in SCLC since 2004 and assessed them using ROBINS-I. We performed I²-tests, Q-statistics, DerSimonian-Laird tests and Egger-regression. The meta-analysis was conducted according to PRISMA.

Results Out of 6826 records, seven studies with a total of 11,241 patients (‘surgery group’: 3911 patients; ‘non-surgery group’: 7330; treatment period: 1984–2015) were included. Heterogeneity between the studies was revealed in absence of any publication bias. Patient characteristics did not differ between the groups (p-value > 0.05). The mean-survival in an analysis of patients in stage I was 36.7 ± 10.8 months for the ‘surgery group’ and 20.3 ± 5.7 months for the ‘non-surgery group’ (p-value = 0.0084). A combined analysis of patients in stage I and II revealed a mean-survival of 32.0 ± 16.7 months for the ‘surgery group’ and 19.1 ± 6.1 months for the ‘non-surgery group’ (p-value = 0.0391). In a separate analysis of stage II, we were able to demonstrate a significant survival benefit after surgery (21.4 ± 3.6 versus 16.2 ± 3.9 months; p-value = 0.0493).

Conclusion Our meta-analysis shows a significant survival benefit after surgery not only in the recommended stage I but also in stage II SCLC. Our data suggests that both stages should be considered for surgery of early SCLC.

Keywords Small-cell lung cancer · Surgery · Meta-analysis · Mean-survival

Introduction

Lung cancer is the most common type of malignant neoplasm with an incidence of approximately two million worldwide [1]. While small-cell lung cancer (SCLC) accounts for only 15% of all malignant lung-tumours, it is the fifth leading cause of cancer death [2]. SCLC is characterized by high-grade malignancy with rapid growth of the primary lesion and early spreading to mediastinal lymph nodes or distant organs [3]. The mean age at the time of SCLC diagnosis is approximately 65 years with tobacco smoke being the main risk factor [2].

Current guidelines recommend curative treatment in stage I to III [4, 5]. Treatment of SCLC is multimodal and typically consists of chemotherapy, radiation and in selected cases a surgical approach [4, 5]. For patients presenting with an extensive disease stage (M1), guidelines suggest palliative rather than curative care [4, 5].

Surgery is currently only recommended for stage I disease (Grade 2C; American College of Chest Physicians (ACCP)), which is diagnosed in approximately 5% of all SCLC cases. [4]. However, a substantially larger fraction of patients (approximately 60%) presents with stage II and III disease and is thus considered unresectable. For these cases, chemotherapy with concurrent radiotherapy is the suggested option [4, 5]. Despite promising early responses, most patients in
these stages relapse. Therefore, surgery to treat SCLC has gained momentum over the past decade not only in stage I disease but also in stage II. Nonetheless, resection as a curative approach beyond stage I remains controversial [6].

The aim of this meta-analysis was to assess the role of surgery in the curative treatment of stage I (T1-T2aN0) and II (T2b-T3N0 or T1-T2N1) SCLC. To achieve this, mean-survival rates were compared between patients who underwent surgery and patients who did not.

**Material and Methods**

**Study Inclusion and Exclusion Criteria**

This unregistered systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [7]. As this work is a meta-analysis an ethics committee approval was not considered. Databases were queried for randomised prospective trials and retrospective studies investigating the effect of surgery in stage I and II SCLC. We only considered work published since 2004. Since staging of lung cancer has changed over the past decades, modern staging tools such as a Computed tomography (CT-scan) were considered mandatory upon study inclusion [8]. An exclusive limitation to staging with Positron Emission Tomography scan (PET-CT) and Magnetic Resonance Imaging (MRI) of the brain was not executed. Consequently, patient recruitment in the original study had to be within the last 35 years to avoid bias due to inaccurate staging. We identified and analysed studies in accordance with the criteria listed in Fig. 1.

The ‘non-surgery group’ was defined as radio-/chemotherapy treatment only, with a majority of patients being treated with a combination of both. All patients who underwent surgical treatment alone or in any combination with neoadjuvant or adjuvant therapy were defined as ‘surgery group’. The definitions of clinical end-points were taken from the primary publications.

**Search Strategy**

Two authors (FD and SS) performed an independent literature search on December 01st 2021 in the Medline, Embase and the Cochrane Library databases. We restricted the languages to English and German. A reference management software (Endnote, Version X9.2, Clarivate Analytics, Spring Garden, Philadelphia, United States) was used to organize all relevant articles. An initial selection was performed by reviewing all titles and abstracts. Full-text was recovered and reference-lists of these papers were further screened to identify other publications fulfilling the above criteria. In case of several publications per patient collective, the study with the most complete dataset was selected for our analysis to avoid inclusion of patients multiple times. Figure 1 provides a detailed flow-chart of the search strategy.

**Data Extraction and Quality Assessment**

All relevant data including demographic data and end-points of interest were extracted from the original studies. The first or the senior author of an original study was contacted in case of missing information. Study quality and risk of bias were assessed by two independent investigators (FD and SS) using ROBINS-I criteria [9].

**Statistical Analysis**

Statistical analysis was performed using the StatsDirect software package (Version 3.2.10, StatsDirect Ltd, Birkenhead, Merseyside, United Kingdom). Throughout our statistical analysis, a p-value < 0.05 was considered significant. We compared treatment groups of each original study with a log-rank test. The hazard ratio (HR) and the 95% confidence interval (95%-CI) of each data set was calculated.
The pooled HR of all studies was analysed and expressed as a Forest plot. Q-statistics (p-value < 0.05) and I²-tests (I² > 50%) were performed to evaluate heterogeneity between studies [10]. In the presence of clinical and statistical heterogeneity, the DerSimonian and Laird random-effects model was implemented [11]. The pooled treatment effect estimate was calculated as a weighted average of the treatment effects so that an HR < 1 favoured the ‘surgery group’ over the control group. Here, the size of squares in the plot displays the sample size. Publication bias was assessed by Egger’s weighted regression statistic with a p-value < 0.05 indicating significant publication bias among included studies.

Results

Literature Search

From an initial set of 6826 papers found in the systematic literature research, seven studies were included in the meta-analysis (Fig. 1). According to ROBINS-I the overall risk of bias in the studies included was low or moderate (Fig. 2). Publication dates ranged between 2004 and 2019 (Table 1). The longest period of patient recruitment was 20 years (1988–2007) performed by Weksler et al. [12]. The most recent paper by Xu et al. had the shortest recruitment period of 6 years (2010–2015) [13]. All studies are retrospective. Five studies are based on national data registries and two studies compile single centre data. Two studies used a pair-match analysis [14, 15] (Table 1).

Despite meeting the inclusion criteria, we excluded six studies from this meta-analysis due to overlapping patient cohorts or similar data sources [16–21]. Data for these six excluded studies is displayed in the lower section of Table 1.

Patient Details

The seven included studies summed a total of 11,241 patients. Of these, 3911 patients are in the ‘surgery group’ and 7330 in the ‘non-surgery group’. Patients’ mean age was 64.2 ± 5.9 years, and 55.3 ± 15.4% of all patients were male. These patient characteristics did not significantly (p-value > 0.05) differ between the ‘surgery’ and ‘non-surgery group’ (Table 2). Further stage-specific analysis on both groups including the level of fitness according to the ‘Charlson/Deyo comorbidity condition’ score (CDCC) are summarized in Table 3.

All patients in the ‘surgery group’ and in the ‘non-surgery group’ received chemotherapy. The only exceptions to this are the studies by Wakeam et al. [15] and Xu et al. [13], in which only 71% (stage I) and 80% (stage II) of the resected patients were treated with chemotherapy, respectively. Furthermore, it must be mentioned that chemotherapy data are not available on the SEER database.

The proportion of patients who received a combination of chemotherapy and radiation therapy in the ‘non-surgery group’ ranged between 50% in the study by Xu et al. and 100% in the study by Yang et al. [13]. Nonetheless, 75% of all patients in the ‘non-surgery group’ were treated with a combined radiochemotherapy.

**Fig. 2** Title: Overall risk of bias according to ROBINS-I
Mean-Survival Analysis in Stage I

The Q-statistic for the mean-survival endpoint was significantly different (p-value = 0.0013) and the I²-test showed 77.6% inconsistency (95%-CI: 23.6–88.9%). This provides evidence for significant statistical heterogeneity between included studies. We therefore implemented the DerSimonian and Laird random-effects model. The pooled hazard ratio was 0.4 (95%-CI: 0.32–0.43) and the Z-test was −13.6 (p-value < 0.0001). This suggests that the ‘surgery group’ showed significant improvement in the mean-survival endpoint compared to control patients (Fig. 3A). Egger’s weighted regression statistic signified that there was no publication bias (p-value = 0.698). Mean-survival was 36.7 ± 10.8 months in the ‘surgery group’ versus 20.3 ± 5.7 months in the ‘non-surgery group’. Therefore, surgical intervention improved mean-survival significantly (p-value = 0.0084) (Fig. 3A).

Mean-Survival Analysis in Stage I and II Combined

Since some groups consider surgical treatment for patients in stage II SCLC, it is plausible to include this sub-population in an analysis together with stage I patients. The Q-statistic for the mean-survival endpoint was significant (p-value = 0.046) and the I²-test suggested 53.3% inconsistency (95%-CI: 0–78.2%), again showing significant heterogeneity between included studies. We applied the DerSimonian and Laird random-effects model as in the other analysis. The pooled hazard ratio of 0.4 (95%-CI: 0.37–0.45) and the
Z-test was −17.9 (p-value < 0.0001). These results suggest a significant survival benefit for patients in stage I and II after surgery (Fig. 3B). Egger’s weighted regression statistic showed no significant publication bias (p-value = 0.0391). Consequently, surgical intervention improved mean-survival in stage I and II SCLC (p-value = 0.0391). Mean-survival was $32.0 \pm 16.7$ months in the ‘surgery group’ versus $19.1 \pm 6.1$ months in the ‘non-surgery group’ (Fig. 3B).

### Mean-Survival Analysis in Isolated Stage II

In order to show that the survival advantage in the combined analysis of both stages is not exclusively due to the good results of stage I, we analysed stage II separately. Here the Q-statistic for the mean-survival endpoint was significant (p-value = 0.0035) and the I²-test suggested 74.4% inconsistency (95%-CI: 3.0–87.7%), again showing significant heterogeneity between included studies. We applied the DerSimonian and Laird random-effects model as in the other analysis. The pooled hazard ratio of 0.4 (95%-CI: 0.33–0.53) and the Z-test was −7.5 (p-value < 0.0001). These results suggest a significant survival benefit for patients in stage II after surgery (Fig. 3C). Egger’s weighted regression statistic showed no significant publication bias (p-value = 0.51). Consequently, surgical intervention improved mean-survival in stage II SCLC (p-value = 0.0493). Mean-survival was $21.4 \pm 3.6$ months in the ‘surgery group’ versus $16.2 \pm 3.9$ months in the ‘non-surgery group’ (Fig. 3C).

### Discussion

#### Guideline-Concordant Use of Surgery in T1/2N0 Situation

The ACCP guidelines give a grade 2C recommendation for surgical therapy in SCLC stage I. In this stage, surgery is preferred over any non-surgical therapy [4]. The National Comprehensive Cancer Network (NCCN) [5] and the American Society of Clinical Oncology (ASCO) [22] recommend resection as initial treatment for node-negative SCLC patients in stage I after pathologic mediastinal staging. The European Society for Medical Oncology (ESMO) recommends surgery for patients in T1/2, N0/1 situation without mediastinal involvement. Surgical therapy should be followed by chemotherapy according to all guidelines.

#### Are Stage I and Stage II SCLC Ready for Surgery?

Several authors, among them Ahmed et al. who recently analysed the SEER database [23], support our opinion that survival is improved by surgery in stage I SCLC. The mean-survival in our meta-analysis was 36.7 months in the ‘surgery group’ versus 20.3 months in the ‘non-surgery group’. Even if stage II is analysed separately, SCLC patients benefit significantly from resection and non-surgical treatment leads to a shortening of survival-time (21.4 versus 16.2 months).

### Table 3  Detailed baseline characteristics

| Age (years) [range / SD] | Surgery group | Non-surgery group | P-value | Stage |
|-------------------------|---------------|-------------------|---------|-------|
| Ahmed                   | 68 [61–73]    | 70 [63–77]        | 0.13    | I     |
| Wakeam                  | 68 [62–74]    | 69 [62–75]        | 0.23    | I     |
| Yang                    | 65.8 [± 8.3]  | 65.7 [± 9.9]      | 0.73    | I     |
| Badzio                  | 57 [29–70]    | 54 [36–71]        | 0.03    | I+II  |
| Weksler                 | 67.8 [± 8.9]  | 68.9 [± 10.1]     | 0.01    | I+II  |
| Zhang                   | 57 [32–75]    | 56 [23–84]        | 0.64    | I+II  |
| Wakeam                  | 67 [59–74]    | 67 [60–74]        | 0.54    | II    |
| Xu                      | 66.6 [± 8.5]  | 68.3 [± 9.4]      | 0.07    | II    |

| Male (%)                 | Surgery group | Non-surgery group | P-value | Stage |
|--------------------------|---------------|-------------------|---------|-------|
| Ahmed                    | 51.0          | 45.3              | 0.26    | I     |
| Wakeam                   | 43.5          | 43.7              | 0.66    | I     |
| Yang                     | 42.9          | 43.8              | 0.68    | I     |
| Badzio                   | 85.0          | 78.0              | 0.27    | I+II  |
| Weksler                  | 48.2          | 48.8              | 0.76    | I+II  |
| Zhang                    | 76.0          | 71.8              | 0.38    | I+II  |
| Wakeam                   | 49.9          | 49.9              | 1.0     | II    |
| Xu                       | 38.6          | 41.5              | 0.63    | II    |

| Race, white (%)          | Surgery group | Non-surgery group | P-value | Stage |
|--------------------------|---------------|-------------------|---------|-------|
| Ahmed                    | 85.0          | 92.8              | 0.02    | I     |
| Wakeam                   | 91.1          | 91.9              | 0.75    | I     |
| Yang                     | 92.4          | 89.9              | 0.01    | I     |
| Badzio                   | 90.5          | 85.9              | 0.01    | I+II  |
| Wakeam                   | 90.7          | 92.2              | 0.68    | II    |
| Xu                       | 89.2          | 85.1              | 0.45    | II    |

| CDCC score 0             | Surgery group | Non-surgery group | P-value | Stage |
|--------------------------|---------------|-------------------|---------|-------|
| Yang                     | 44.8          | 64.9              | 0.01    | I     |
| Wakeam                   | 49.0          | 50.8              | 0.65    | I     |
| Badzio                   | 60.0          | 58.0              | 0.57    | I+II  |
| Wakeam                   | 49.6          | 46.6              | 0.59    | II    |

| CDCC score 1             | Surgery group | Non-surgery group | P-value | Stage |
|--------------------------|---------------|-------------------|---------|-------|
| Yang                     | 39.8          | 24.7              | 0.01    | I     |
| Wakeam                   | 36.2          | 35.2              | 0.65    | I     |
| Badzio                   | 36.0          | 33.0              | 0.57    | I+II  |
| Wakeam                   | 37.9          | 41.8              | 0.59    | II    |

| CDCC score 2 +           | Surgery group | Non-surgery group | P-value | Stage |
|--------------------------|---------------|-------------------|---------|-------|
| Yang                     | 15.4          | 10.4              | 0.01    | I     |
| Wakeam                   | 14.8          | 14.1              | 0.65    | I     |
| Badzio                   | 4.0           | 9.0               | 0.57    | I+II  |
| Wakeam                   | 12.5          | 11.6              | 0.59    | II    |

Bold values denote statistical significance at the p < 0.05

CDCC Charlson/Deyo comorbidity condition, SD standard deviation

Z-test was $-17.9$ (p-value < 0.0001). These results suggest a significant survival benefit for patients in stage I and II after surgery (Fig. 3B). Egger’s weighted regression statistic showed no significant publication bias (p-value = 0.925). Consequently, surgical intervention improved mean-survival.
At this point, we would like to point out that some patients that were included in this meta-analysis were potentially not staged with PET-CT and MRI of the brain. It is not to be expected that the results of our meta-analysis would significantly change as a result of including the six studies that were excluded due to overlapping patient cohorts from similar data sources. Uprety et al. report a 30-month survival benefit for surgical patients in stage I of the NCDB database [19]. The SEER database was sourced by several authors. Schreiber et al. and Varlotto et al. report on stage I patients from the SEER database between the years 1988 to 2005. In these studies, the authors showed a survival benefit of 50 and 30 months, respectively [18, 20]. Three studies (Jin et al., Peng et al., and Wang et al.) analysed mean-survival of stage I and stage II SCLC patients from the SEER database between 2004 and 2015. The mean-survival benefit in these studies ranged from 10 to 15 months [16, 17, 21]. Furthermore, Zhu et al. published a single centre study in 2013 and reported a significant mean-survival benefit for surgically treated patients in stage I and II compared to patients treated with chemoradiotherapy (91.0 months versus 34.6 months; p-value: 0.004) [24]. This study could not be included into our meta-analysis since some relevant data were not reported by the authors.

Our meta-analysis data provide evidence for a significant mean-survival benefit after surgery in early-stage SCLC. This finding might suggest expanding the role of surgery to stage II SCLC, for which there is currently no clear guideline recommendation for resection. We believe that stage I and stage II SCLC are ready for surgery.

No Improvement on Prognosis of SCLC Since Decades

Unlike NSCLC, in which the treatment options have been revolutionized in recent years and the prognosis has been significantly improved even for advanced stages, the overall 5-year survival rates in SCLC remain below 10% [25]. But there is a glimpse of hope. Today, with a better understanding of the SCLCs biology, we have numerous therapeutic options, not least targeted immunotherapies [26]. Recently we showed that SCLC displays an actionable dependence on ATR/CHK1-mediated cell cycle checkpoints [27]. Nevertheless, potential cellular and molecular mechanisms need to be further investigated. We share the opinion of Byers et al. that translational SCLC research is severely affected by the limited access to human tumour tissue [25].

Resection Rates Need to Increase, But How Radical Do We Have to Operate?

In accordance with the guidelines, surgery should be preferred to non-surgical therapy in stage I as it improves long-term prognosis [4, 5]. However, the number of operations stagnated in the past decade [23] and has reached only 10% in potentially resectable patients [6]. Today, less than a third of all stage I patients are evaluated for surgery [6, 15, 23]. It follows that surgery is significantly underused in SCLC [28]. The data of Weksler et al. indicate that wedge resection results in significantly worsened median survival compared to lobectomy or pneumonectomy (39 months versus 28 months, p-value < 0.001) [12]. According to Schreiber et al. the median survival-time was longest after lobectomy, followed by sublobar resection, pneumonectomy and lack of surgery (40 months, 23 months, 20 months and 13 months, respectively) [18]. In 2018 Che et al. reported a median survival of 34 months after lobectomy. Any type of sublobar resection resulted in a shorter median survival of 17 months [29]. In this context, it is interesting that Varlotto et al. provide evidence of optimal local control after lobectomy which leads to superior survival. The authors suggest inferior outcome after sublobar resection compared to lobectomy, but
they report a survival advantage of both surgical techniques compared to radiotherapy alone [20].

This section shows the importance of surgery in SCLC, especially with a focus on lobectomy. In attempt to avoid a pneumonectomy it is not uncommon to perform a sleeve resection in SCLC due to centrally growing tumours [30]. Since it is important to assess the need of postoperative radiation of the mediastinum a systematic lymph-node dissection should always be performed beside lobectomy [31].

Is the Impact of Surgery on Long-Term Survival Really That Great?

The survival benefit of surgery in stage I and stage II SCLC appears impressive in this meta-analysis. Could there be an underestimated bias of patient selection? It is possible that it is not the surgery itself, but rather the selection factors enabling surgery, that play a critical role in favourable outcomes. Hence, it is debatable, whether patient selection or surgery lead to favourable outcomes.

The subset of SCLC patients eligible for surgery is characterized by early clinical stage with less tumour burden, good physical performance and lack of significant comorbidities [20, 28]. Consequently, these patients have a better prognosis irrespective of whether surgical treatment is attempted or not. This favourable preselection might influence the results of the published studies and distort the efficacy of surgery in SCLC [6, 14]. We addressed this potential bias due to preselection in our meta-analysis by evaluating performance scores such as ECOG (Eastern Cooperative Oncology Group) to assess the fitness of patients in both groups whenever possible. Nevertheless, not all original studies performed a pair-matching in regard of the patients’ fitness. Since such scores were not reported regularly, patients that underwent surgery might have had a better health status at time of intervention than their non-surgical counterparts. Consequently, a bias due to confounding might exist in selected cases.

The Pre 90 s RCTs Are Still the Spoilsport for Surgery Today

Current surgical guidelines in SCLC are largely based on three RCTs by Fox et al. [32], Lad et al. [33] and Liao et al. [34], which undoubtedly guarantee the best level of evidence [35], and which show little to no improvement of surgery over alternate treatment options. A recent Cochrane review pointed out difficulties in these studies’ interpretation under today’s standards [36]. We believe that evaluating the role of surgery in SCLC based on these three RCTs seems not justified today due to several reasons. First, the patients’ recruitment period already started in 1962 [32]. Second, the total number of patients is small and the staging procedures led to inclusion of participants in advanced SCLC stages, which would not be suitable for surgery today. Third, the treatment in these RCTs is heterogeneous and does not fulfill today’s surgical standards and recommendations especially in regard of the high number of pneumonectomies’ and explorative thoracotomies. Lastly, results after surgery are biased due to a high percentage of incomplete or not executed resections. Despite all, Lad et al. and Liao et al. do not report a significant inferiority of surgical treatment [33, 34].

Conclusion

We provide a meta-analysis on stage I and stage II SCLC patients that reveals superior long-term outcome after surgery. Patients in both stages gain significant lifetime through resection. Based on data of our meta-analysis, we believe that SCLC patients in stage I and stage II should be considered for surgery. All analysed data in this systematic review are of a retrospective nature. Today this might still be the top of the pyramid of evidence-based medicine. Nevertheless, we want to urgently call for a high quality and high volume multi-institutional randomized control trial on the role of surgery in SCLC, which clearly has the potential to change future guidelines.

Acknowledgements We want to thank Prof. N. Skoetz (Evidence-based Oncology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany) for her statistical advice. We thank Prof. J. Wolf and J.P. Weber (Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany) for their oncological advice. Furthermore, we thank Dr. L. Hagmeyer (Clinic for Pneumology and Allergology, Bethanienn Hospital gGmbH Solingen, Germany) for his advice on pneumological questions.

Author Contribution All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by FD, SS, HM, GS and MM. The first draft of the manuscript was written by FD and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of Interest The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. The authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
2. Dayen C, Debieuvre D, Molinier O et al (2017) New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases. J Thorac Dis 9:5101–5111
3. Moreno AC, Lin SH (2019) The optimal treatment approaches for stage I small cell lung cancer. Transl Lung Cancer Res 8:88–96
4. Jett JR, Schild SE, Kesler KA et al (2013) Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e400S – e419
5. Kalemkerian GP, Akerley W, Bogner P et al (2013) Small cell lung cancer. J Natl Compr Canc Netw 11:78–98
6. Combs SE, Hancock JG, Boffa DJ et al (2015) Bolstering the case for lobectomy in stages I, II, and IIIA small-cell lung cancer using the National Cancer Data Base. J Thorac Oncol 10:316–323
7. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
8. Verschakelen JA, Bogaert J, De Wever W (2002) Computed tomography in staging for lung cancer. Eur Respir J Suppl 35:40s–48s
9. Sterne JA, Hernán MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919
10. Cleophas TJ, Zwinderman AH (2007) Meta-analysis. Circulation 115:2870–2875
11. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
12. Weksler B, Nason KS, Shende M et al (2012) Surgical resection should be considered for stage I and II small cell carcinoma of the lung. Ann Thorac Surg 94:889–893
13. Xi L, Zhang G, Song S et al (2019) Surgery for small cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 2010 to 2015. Medicine (Baltimore) 98:e17214
14. Badzio A, Kuroswi K, Karnicka-Modkowska H et al (2004) A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 26:183–188
15. Wakeam E, Acuna SA, Leighl NB et al (2017) Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival. Lung Cancer 109:78–88
16. Jin K, Zhang K, Zhou F et al (2018) Selection of candidates for surgery as local therapy among early-stage small cell lung cancer patients: a population-based analysis. Cancer Commun (Lond) 38:5
17. Peng A, Li G, Xiong M et al (2019) Role of surgery in patients with early stage small-cell lung cancer. Cancer Manag Res 11:7089–7101
18. Schreiber D, Rineer J, Weedon J et al (2010) Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer 116:1350–1357
19. Upreti D, Arjyal L, Vallatharasu Y et al (2020) Utilization of surgery and its impact on survival in patients with early stage small-cell lung cancer in the United States.Clin Lung Cancer 21:186–193.e2
20. Varlotto JM, Recht A, Flickinger JC et al (2011) Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis. J Thorac Cardiovasc Surg 142:538–546
21. Wang Y, Zheng Q, Jia B et al (2020) Effects of surgery on survival of early-stage patients with SCLC: propensity score analysis and nomogram construction in SEER database. Front Oncol 10:626
22. Rudin CM, Ismaila N, Kann CL et al (2015) Treatment of small-cell lung cancer: american society of clinical oncology endorsement of the American College of Chest Physicians guideline. J Clin Oncol 33:4106–4111
23. Ahmed Z, Kujtan L, Kennedy KF et al (2017) Disparities in the management of patients with stage I small cell lung carcinoma (SCLC): a surveillance, epidemiology and end results (SEER) analysis. Clin Lung Cancer 18:e315–e325
24. Zhu H, Zhou Z, Xue Q et al (2013) Treatment modality selection and prognosis of early stage small cell lung cancer: retrospective analysis from a single cancer institute. Eur J Cancer Care (Engl) 22:789–796
25. Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer 121:664–672
26. Wang S, Zimmermann S, Parikh K et al (2019) Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc 94:1599–1622
27. Dorer F, George J, Schmitt A et al (2017) Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Sci Rep 7:15511
28. Yang CJ, Chan DY, Shah SA et al (2018) Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer. Ann Surg 268:1105–1112
29. Che K, Shen H, Qu X et al (2018) Survival outcomes for patients with surgical and non-surgical treatments in stages I–III small-cell lung cancer. J Cancer 9:1421–1429
30. Welter S, Aigner C, Roesel C (2017) The role of surgery in high grade neuroendocrine tumours of the lung. J Thorac Dis 9:1474–1483
31. Domine M, Moran T, Isla D et al (2020) SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol 22:245–255
32. Fox W, Scadding JG (1973) Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-cell or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet 2:63–65
33. Lad T, Piantadosi S, Thomas P et al (1994) A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106:320s–323s
34. Liao M, Zhao J, Zhou Y (1995) Multimodality therapy of late stage lung cancer. Zhonghua Zhong Liu Za Zhi 17:384–386
35. Engellhardt KE, Odell DD, Decamp MM (2017) Under-treatment of small cell lung cancer: the case for surgical resection. J Thorac Dis 9:5309–5313
36. Barnes H, See K, Barnett S et al (2017) Surgery for limited-stage small-cell lung cancer. Cochrane Database Syst Rev 4:Cd011917

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.